APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Probes, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
We pay the most careful attention to the quality of our products. All products are manufactured with rigorous guidelines and are accompanied with certificates of analysis, HPLC, Mass Spectrum, and HMNR, as well as in vitro validation. APExBIO products have been cited by many top peer-reviewed journals such as Nature, Cell and Science.
Biologists and Chemists at APExBIO offer extensive tech support to our customers for using the products. You may expect personalized and attentive care from our support staff answering your order and technical inquiries. We also provide custom services including peptide synthesis, custom mRNA synthesis and assay development.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.
Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.
Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.
Custom Biologics provide exceptional, high quality, customized assays to measure the functional properties of cellular and biotherapeutic drug candidates. We are a Health Canada audited, GMP-compliant, global service provider for functional testing of biotherapeutics, biosimilars and antibody drug conjugates.
For over 14 years our scientists have been designing and validating sophisticated bioanalytical assays, to characterize and measure the therapeutic potential of large and small molecule biotherapeutics.
Our work supports regulatory drug submission applications from biopharmaceutical companies throughout North America, Europe and Asia.
Great Science - It's at the heart of everything we do!
DCN Dx specializes in contract development of rapid point of care tests. We offer a variety of services and products that assist our clients in the design and development of user-centric, high performing diagnostic devices.
Contract development of rapid immunoassays is at the core of all that we do at DCN Dx. We focus on lateral flow, flow through, and microfuidic formats. Our staff has unparalleled experience in developing assays with tough specifications, regarding high sensitivity, quantification, multiplexing and reader integration. Our ISO 9001:2015 compliant development process allows for close integration of assay and device development pathways, which ensures the best chance of commercial success for the product.
As well as developing the assay itself, DCN Dx's integrated engineering team will design, develop and integrate your entire device. The engineers work closely with our scientists to create cassettes and sample handling devices that enhance the performance of your assay and meet all end-user specifications. We deliver the product, not just the parts.
DCN Dx also offers a variety of products and services to assist our clients at any stage of development, including:
- Custom, private education and training courses in lateral flow technology, during which we teach the details of how to develop and manufacture rapid assays.
- Consulting services to assist with any aspect of rapid assay development, manufacturing, regulation and commercialization.
- Custom protein-protein, protein-particle, small molecule-protein and small molecule- particle conjugations.
- Lateral flow material starter kits, conjugation kits, reagents, cassettes and materials for use during rapid assay development.
DCN Dx represents a single source that can help you manage and deliver completely validated assay platforms.
MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism, and pharmacokinetic analysis to support discovery, preclinical, and clinical drug development studies. We specialize in method development, validation, and sample analysis of small molecules, macromolecules, biomarkers, and metabolites using LC/MS/MS, HPLC/UV, immunoassay, multiplex, and qPCR techniques.
Since 1998, we have been advancing the drug discovery and development programs of pharmaceutical and biotech companies worldwide. To learn more, please visit http://www.microconstants.com.